Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers
Precipio's Q3 2025 revenue increased by 30% year-over-year to $6.8 million, driven by new customer acquisitions. The company achieved a positive adjusted EBITDA, improving by over $500,000 from Q2, and generated $285,000 in cash from operations. Revenue growth was attributed to a 20% increase in pathology services and a 16% rise in the product division. The company expects gross margins to approach 50% due to operational efficiencies and financial discipline.
)
Overview
- Precipio Q3 2025 revenue grows 30% YoY to $6.8 mln
- Adjusted EBITDA turns positive in Q3 2025, improving by over $500K from Q2
- Company generates $285K cash from operations in Q3 2025
Outlook
- Company anticipates gross margins to increase towards 50%
Result Drivers
- PATHOLOGY SERVICES GROWTH - Revenue increased 20% due to new customer accounts in the pipeline
- PRODUCT DIVISION EXPANSION - Revenue rose 16% from existing customers and new panel orders
- OPERATIONAL EFFICIENCIES - Positive EBITDA and cash generation attributed to operational efficiencies and financial discipline
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 $6.80
Revenue mln
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
